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Abstract
Immunosuppressive regulatory T cells (Tregs) have been hypothesized to exert a protective role in animal models of
spontaneous (Buffalo/Mna) and/or drug induced (Adriamycin) nephrotic syndrome. In this study, we thought to define
whether Tregs can modify the outcome of LPS nephropathy utilizing IL-2 as inducer of tissue and circulating Tregs. LPS
(12 mg/Kg) was given as single shot in C57BL/6, p2rx72/2 and Foxp3EGFP; free IL-2 (18.000 U) or, in alternative, IL-2 coupled
with JES6-1 mAb (IL-2/anti-IL-2) were injected before LPS. Peripheral and tissue Tregs/total CD4+ cell ratio, urinary
parameters and renal histology were evaluated for 15 days. IL-2 administration to wild type mice had no effect on peripheral
Tregs number, whereas a significant increase was induced by the IL-2/anti-IL-2 immunocomplex after 5 days. Spleen and
lymph nodes Tregs were comparably increased. In p2rx72/2 mice, IL-2/anti-IL-2 treatment resulted in increase of peripheral
Tregs but did not modify the spleen and lymph nodes quota. LPS induced comparable and transient proteinuria in both
wild type and p2rx72/2 mice. Proteinuria was inhibited by co-infusion of human IL-2, with reduction at each phase of the
disease (24 248 and 72 hours) whereas IL-2/anti-IL-2 produced weaker effects. In all mice (wild type and p2rx72/2) and
irrespective of treatment (IL-2, IL-2/anti-IL-2), LPS was associated with progressive signs of renal pathologic involvement
resulting in glomerulosclerosis. In conclusion, IL-2 plays a transient protective effect on proteinuria induced by LPS
independent of circulating or tissue Tregs but does not modify the outcome of renal degenerative renal lesions.
Citation: Bertelli R, Di Donato A, Cioni M, Grassi F, Ikehata M, et al. (2014) LPS Nephropathy in Mice Is Ameliorated by IL-2 Independently of Regulatory T Cells
Activity. PLoS ONE 9(10): e111285. doi:10.1371/journal.pone.0111285
Editor: Partha Mukhopadhyay, National Institutes of Health, United States of America
Received July 21, 2014; Accepted September 25, 2014; Published October 24, 2014
Copyright:  2014 Bertelli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and
supporting information files.
Funding: This work was also supported by the Italian Ministry of Health ‘Ricerca Corrente’ and from contributions derived from ‘Cinque per mille
dell’IRPEF’(5xMIL RIC 12 D.74/13L.2.). Contributions also were obtained from the Renal Child Foundation (FMRB; www.fmrb.it) and from Fondazione La Nuova
Speranza (www.lanuovasperanza.org) supporting the grant:‘Progetto integrato per la definizione dei meccanismi implicati nella glomerulosclerosi focale’. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: GMarcoGhiggeri@ospedale-gaslini.ge.it
. These authors contributed equally to this work.
Introduction
Glomerulonephritis potentially derive from a direct immuno-
modulatory effect of circulating blood cells, antibodies, cytokines
and other mediators on the kidney. [1,2,3] Autoimmune diseases
are an example but there are also less defined conditions such as
nephrotic syndrome, for which evidence for an immunomediated
mechanism is accumulating in animal models and in humans. In
fact, oxidants are known to mediate inflammation in experimental
models [4,5] and there is indirect evidence for oxidant hyperac-
tivity in humans with nephrotic syndrome; [6,7,8,9] co-stimulatory
molecules may also be activated in some instance [10,11]. The
Lipopolysaccharide (LPS) model of proteinuria is of particular
interest in studying the immunomodulatory link: mice lacking the
B7-1 (a co-stimulatory molecule) are, in fact, protected from
developing proteinuria [10] and proteinuria protection has been
proposed, albeit with controversy [12], in nephrotic patients using
the inhibitor of B7-1 molecule abatacept. [11]. There is convincing
evidence that LPS is directly active on podocytes and is
independent of T or B cells. Experiments in SCID mice, which
are devoted of both cell lineages but still develop proteinuria after
LPS, are central to this demonstration. [10].
Circulating cells deputed to regulation of the immune response,
in particular CD4+, potentially play a regulatory role in LPS (and
in other experimental and human nephropathies as well) if their
level is increased by drugs. One possibility is that CD4+
exacerbate the glomerular damage by differentiating into Th17
or by recruiting macrophages and neutrophils [13] [14]; they may
also act as negative feedback effectors of the adaptive immune
response by differentiating into CD4+ CD25+ regulatory T cells
(Tregs). [15] The thin demarcation between pro-inflammatory
and anti-inflammatory pathways is crucial in determining the
outcome in many renal diseases.
The enhancement of Tregs function represent an attractive
therapeutic approach in treating many autoimmune and inflam-
matory renal disorders [16]. Positive results were obtained with
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Tregs expansion in experimental crescentic nephropathy [17] and
in different models of nephrosis arising spontaneously [18] in
Buffalo/Mna rats or induced by Adriamycin [19]. In both cases,
Tregs have been directly infused in rats with experimental
nephrosis [18,19], or have been up-regulated with exogenous
IL-2 [17]. A partial improvement of renal function and a
reduction of tissue lesions were obtained.
Studies with IL-2 in humans are limited to cryoglobulinemia in
which case infusion of low dose IL-2 was followed by an increase
in Treg and was associated with clinical improvement [20].
In this study, we examined the effects of Tregs induction by IL-2
on the onset and progression of LPS nephropathy, a transient
model of proteinuria [10]that determines renal lesions similar to
focal segmental glomerulosclerosis in humans. Two models for IL-
2 treatment were utilized on the basis of different cell subset
activity of IL-2 when infused as free cytokine or otherwise coupled
with anti-IL-2 JES6-1 antibodies (IL-2/anti-IL-2); in the latter case
the IL-2/anti-IL-2 complex plays a selective effect on the IL-2-Ra
chain (CD25) that is highly expressed in Tregs [21]. The role of
ATP as potential inducer of the renal damage and/or as
modulator of circulating and tissue Tregs was in parallel evaluated
by utilizing mice lacking the P267 receptor and for this reason less
prone to inflammatory stimuli [22].
Materials and Methods
Ethical statement
Experiments in mice were done according to the principles
expressed in the Declaration of Helsinki and were approved by the
Institutional Review Board of IRCCS S. Martino (Genoa) and by
the local authorities according to the legal requirements.
Animals
Six- to eight-week-old male C57BL/6 mice (weight 20–25 g)
were purchased from Harlan Laboratories (Indianapolis, IN,
USA). P2rx72/2 (B6.129P2-P2rx7tm1Gab/J) and ‘‘Foxp3EGFP’’
(B6.Cg-Foxp3tm2Tch/J) were from Jackson Laboratories (Bar
Harbour, ME, USA) and were backcrossed to obtain p2rx72/
2/Foxp3EGFP mice.
IL-2 and IL-2/anti-IL-2 infusion
Where indicated, for 14 days before LPS treatment, mice were
given daily an intra-peritoneal injection of human recombinant
IL-2 (18.000 U in 100 ml) (Proleukin, Novartis, Basel, Switzer-
land). In the case of IL-2/anti-IL-2 complex, mice were treated for
5 days prior to LPS, with 1 mg mouse recombinant IL-2 previously
mixed and incubated at 37uC for 30 minutes with 5 mg anti-mouse
IL-2 monoclonal antibody (clone JES6-1) (Sigma Aldrich, St.
Louis, MO, USA) as described by other Authors [21,23].
Experimental LPS nephropathy
For induction of LPS nephropathy, all mice were injected intra-
peritoneal with 12 mg/Kg LPS (serotype 0111:B4, Sigma Aldrich,
St Louis, MO, USA) dissolved in sterile LPS-free PBS in a total
volume of 100 ml/mouse, or with an equal volume of sterile LPS-
free PBS, as previously described by Reiser [10]; after 24, 48 and
72 hours urines were collected for monitoring proteinuria. Blood
samples for determination of circulating Tregs were obtained at
different times from IL-2 and/or IL-2/anti-IL 2 infusions. In the
former case, blood samples were obtained at T0, T14 (corre-
sponding to the intervals utilized for IL-2 induction of Tregs) and
after 3 further days from LPS. In the case of IL-2/anti IL-2, blood
was obtained at T0, T5 days (corresponding to the interval utilized
for Treg induction) and after 3 further days from LPS. Spleen and
lymph nodes Tregs were determined at the end of the experiments
corresponding to +T17 from IL-2 infusion and +T8 from IL-2/
anti-IL-2.
For renal pathology, mice were sacrificed 7 days from LPS.
Determination of albumin
Urinary albumin was separated by 10% SDS-PAGE, and
identified by immunoblotting, using a goat polyclonal anti-mouse
albumin antibody (Santa Cruz Biotechnology Inc, Dallas, TX,
USA) and an alkaline phosphatase-conjugated anti-goat as
secondary antibody (Santa Cruz Biotechnology Inc, Dallas, TX,
USA). The blot was then developed with nitro blue tetrazolium
chloride/5-bromo4-chloro-3-indolyl phosphate (NBT/BCIP) re-
agents (Roche Diagnostics GmbH, Mannheim, Germany). In
order to quantify the mouse albumin bands the blots were
digitalized and a densitometry was performed by using the
software NIH ImageJ v. 6.4 (freeware, NIH, Bethesda, MD, USA).
A known quantity (1–3 mg) of mouse albumin (Sigma-Aldrich, St.
Louis, MO, USA) was used as reference.
TLR4 western blot
Where indicated we used an anti-TLR4 monoclonal antibody
(sc-293072 Santa Cruz Biotechnologies, Dallas, TX, USA) and a
goat anti-mouse alkaline-phosphatase conjugated antibody as
secondary antibody (sc-2008 Santa Cruz Biotechnolgies, Dallas,
TX, USA).
Flow cytometry for Tregs analysis
For determination of Treg number, peripheral blood was
collected at different times by retro-orbital bleeding; PBMC were
isolated using Erythrocyte Lysing Reagent (Uti-Lyse, Dako,
Glostrup, Denmark), according to manifacturer’s instructions,
stained with anti- mouse CD4-PE monoclonal antibody (Santa
Cruz Biotechnology, Dallas, TX, USA) for 20 minutes at room
temperature and analyzed by flow cytometry technique on BD
FACSCanto II instrument with FACSDiva Software. Spleen and
draining lymph nodes specimens were harvested at 72 hours after
LPS administration, minced and pressed onto 40 mm Cell
Strainers (BD Falcon, San Jose`, CA, USA), to obtain a
monocellular suspension; for identification of double–positive
CD4+ Foxp3+ cells, after erythrocyte lysis with ACK buffer, cells
were stained with PE-coniugated anti-mouse CD4 (Santa Cruz
Biotechnology Inc, Dallas, TX, USA). and analyzed by flow
cytometry as above described.
Histochemistry
Renal tissues for light microscopy were fixed in 4% buffered
paraformaldehyde and embedded in paraffin; 3 mm sections were
cut, deparaffinised, rehydrated, and stained with Hematoxilin/
Eosin, PAS, and Trichrome according to standard techniques.
Evaluation of main histological parameters (i.e. mesangial
hypercellularity, mesangial matrix expansion, segmental glomer-
ulosclerosis, tubular casts, tubular atrophy, interstitial infiltration,
interstitial fibrosis) was performed semiquantitatively by two
independent observers not aware of the mouse genotype and
treatment. Glomerular evaluation was performed on a minimum
of 40 glomeruli per section.
Results
LPS induced nephropathy
Intraperitoneal infusion of LPS in mice triggers an inflamma-
tory cascade and is sometimes associated with lethal septic shock.
LPS also induces variable and transient proteinuria, typically
IL-2, Tregs and LPS Nephropathy
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beginning 24 hours after the infusion and lasting for 72 hours
when a rapid decline is followed by normalization. In our hands
albuminuria varied from 15 mg/dl at 24 hours to 10 mg/dl at 48
hours and 5,3 mg/dl at 72 hours (Figure 1). Renal histology was
characterized by mesangial proliferation and mesangial matrix
espansion that were evident at 24 hrs from LPS infusion and
increased over time. After 7 days also segmental glomerulosclerosis
was present and relevant in terms of glomeruli involved (30–
50%)(Figure 2).
LPS induced nephropathy is not dependent on
extracellular ATP
The ATP gated ionotropic P267 receptor participates in
NLRP3 inflammasome activation and in sensing extracellular
ATP released by tissue damage. Its blockade was shown to
attenuate murine lupus nephritis [24]. In addition it was recently
shown that Tregs lacking P267 are more stable and efficient as
immunosuppressive cells in inflammatory bowel disease [25]. To
address whether ATP release and signalling via P267 receptor
were involved in LPS induced nephropathy, we injected LPS in
p2rx72/2 mice. However, lack of P267 did not result in
amelioration of proteinuria after LPS treatment (Figure 1) and
the outcome of proteinuria maintained the same characteristics of
LPS treated wild type mice with spontaneous remission occurring
after 72 hours from LPS infusion. Renal histology was not
modified as well (Figure 2).
Proteinuria is modified by human IL-2 in LPS
nephropathy
LPS nephropathy was inhibited by co-infusion of human IL-2,
in which case proteinuria was reduced at each phase of the disease
(7 mg/dl at 24 hours after LPS, 4,8 mg/dl at 48 hours and
0,8 mg/dl after 72 hours) (Figure 1). Co-infusion of mouse IL-2
coupled with JES6-1 mAb (IL-2/anti-IL-2) produced weaker but
still significant reduction of proteinuria at each phases of the
disease (Figure1).
In p2rx72/2 mice, the effect of IL-2 pre-treatment on
proteinuria was negligible at 24 hours (13,3 mg/dl) while being
evident after 48 and 72 hours from LPS, (e.g. 2,4 mg/dl and
0,7 mg/dl respectively (Figure 1); thus, in absence of the P267
receptor, IL-2 seems to influence disease progression without
modifying proteinuria at the onset.
Once again, this protective effect was less evident in mice pre-
treated with IL-2/anti-IL-2 (Figure 1): in this case, persistent and
comparable levels of proteinuria were found in p2rx72/2 mice,
irrespectively of cytokine pre-treatment, in the entire observation
period.
Histological parameters were similar in all phases of proteinuria
and were not modified by IL-2 nor by IL-2/anti-IL-2 infusion
(Figure 2A, B).
Treg levels are regulated by IL-2/Anti-IL-2
For the experiments on Tregs regulation by IL-2, we utilized
Foxp3EGFP mice that allow easy detection of Tregs in circulation
and tissues due to spontaneous fluorescence. As shown in
Figure 3A, IL-2 administration to wild type mice had no effect
on peripheral Tregs number, whereas a significant increase in
CD4+ Foxp3+/total CD4+ cell ratio was induced in peripheral
blood by the IL-2/anti-IL-2 (i.e 21,661.23 compared to
9.0460.28 in untreated animals) after 5 days from infusion. The
same Tregs number remained elevated and was not modified by
LPS (Figure 3A). Analysis of tissue Tregs at 72 hours after LPS
treatment confirmed the increment of Tregs produced by IL-2/
anti-IL-2 in spleen and lymph nodes (Foxp3+/CD4+ ratio
43.3565.34 vs. 22.1563.77) (Figure 3B). Once again, IL-2 did
not significantly modify this value at any time.
The effect of IL-2/anti-IL-2 on peripheral Tregs was evident
also in p2rx72/2/Foxp3EGFP mice (21.761.1 vs.10.660.4 in
untreated mice) with a slight reduction after LPS treatment
(18.0660.87 in LPS treated versus 21.6661.10 in mice before
treatment) (Figure 3A). In spleen and in lymph nodes of p2rx72/
2/Foxp3EGFP mice the positive regulation of IL-2/anti-IL-2 was
absent (Figure 3B).
Urine TLR-4 levels are modified by IL-2
LPS infusion in mice markedly increased urinary levels of TLR-
4 during the 24 hours after infusion after then decreased by 80%
after 72 hours (Figure 4). Combination of IL-2 and LPS produced
a near normalization of urinary TLR-4 levels that after 24 hours
from LPS were only slightly increased and after 72 hours only
minimally detectable. IL-2/anti-IL-2 produced intermediate
effects: after 24 hours from LPS, urinary TLR-4 levels were
40% than in mice treated with LPS alone and then decreased
following the same outcome.
Discussion
This work was aimed at addressing a possible protective role of
Tregs in experimental nephropathy induced by LPS that is a
model of transient proteinuria associated with foot process
effacement, resembling human minimal change nephrosis
[10,26,27] and evolving to glomerulosclerosis. LPS is sensed in
podocytes by Toll-like receptor 4 (TLR-4) and up-regulates the co-
stimulatory molecule B7-1 [28,29]. From one side, the conse-
quence is activation of an immune response, from the other is the
reorganization of the actin cytoskeleton producing effacement of
podocyte slit-diaphragm and proteinuria [10]. Overall, LPS
nephropathy represents a suitable model to study the link between
the innate immune response (TLR-4/B7-1) and the kidney and is,
more in general, considered a reliable approach to study
mechanisms of nephrotic syndrome. Studies addressing the direct
effect of LPS on B7-1 are of particular interest since B7-1
activation in podocyte may be blunted by using the inhibitor of
B7-1 molecule abatacept. [11,12] Activation of B7-1 has also been
shown in human beings with nephrotic syndrome that potentially
suggests abatacept could be used in these patients [27,30].
Few studies focused on the long-term effect of cytoskeleton re-
organization in podocytes as modified by LPS. We know from
familial cases of genetic nephrotic syndrome that mutations in
cytoskeleton components lead to degeneration of glomerular tuft
even if proteinuria is often mild. [31,32,33,34] We could show
here that, in spite of transient proteinuria, renal histology after
LPS evolves in a few days to extensive glomerulosclerosis (30–50%
of glomeruli). This is a new finding that strengthens LPS as a
model of renal glomerulosclerosis (FSGS) and mimics what
happens during years in patients carrying genetic variants of
cytoskeleton genes [35].
A potential protective role of Tregs on LPS nephropathy was
suggested by results in other experimental nephrosis (i.e in
Buffalo/Mna rats and in Adriamycin nephrosis) that are, in the
same way of LPS, two recognized models of proteinuria leading to
glomerulosclerosis and renal failure [18] [19]. For enhancing
Tregs function we utilized IL-2 since this cytokine plays an
important role in Tregs growth, survival and activity in both mice
and humans. IL-2 was utilized as free cytokine or in a complex
with the JES6-1 anti-IL-2 antibody (i.e. IL-2/anti-IL-2), which
plays different effects on T cell lineages. In fact, IL-2 activates
IL-2, Tregs and LPS Nephropathy
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Figure 1. Proteinuria outcome in LPS mice. Urinary albumin levels were evaluated with immune-western after LPS (12 mg/Kg) treatment
(24 hrs, 48 hrs and 72 hrs after treatment) in wild C57BL/6 and in P2672/2 mice. In some cases and in both experimental groups (WT and P2672/2)
IL-2 (18.000 U) and/or IL-2/anti-IL-2 were infused prior LPS to regulate circulating and tissue Tregs (see Figure 3). * = p#0.05, ** = p#0.005, *** = p#
0.0005.
doi:10.1371/journal.pone.0111285.g001
IL-2, Tregs and LPS Nephropathy
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CD4+, CD8+ T cells, Tregs and NK cells through different
regions of the same IL-2 receptor composed of three subunits, i.e.
a, b and c that are differently expressed in CD8+ and NK cells
versus Tregs [36]. Free IL-2 activates both the high affinity and
the intermediate affinity receptor IL-2Rb chain that is specific for
memory CD8+ and NK cells, whereas when coupled with JES6-1
the IL-2 binding is restricted to the IL-2Ra chain (CD25) that is
highly expressed on Tregs [21]. The effect of IL-2/anti-IL-2
complex on CD25- (hence on CD8+ and NK cells) is null, whereas
it is maximal on Tregs. Indeed, Tregs expansion by IL-2/anti-IL-2
is protective in experimental models of allergy [16] and for the
kidney it has been utilized with positive results in experimental
crescentic glomerulonephritis [17] and in the renal ischemia-
reperfusion injury [37]. As second model of protection from
immunopathological damage, we exploited mice lacking the P267
receptor in which responsiveness of innate immune cells to tissue
damage is weakened and Tregs are more stable and less prone to
convert into pro-inflammatory cells [25,38]. Moreover, podocytes
silenced for P267 present a blunt response of inflammasome
proteins to LPS suggesting some protection. [39].
Figure 2. Histology features. Classical histology (Ematoxylin Eosin, PAS) of kidney biopsies was evaluated after several times from LPS infusion
(24hrs, 72 hrs and 7 days). Three main features were observed: 1-mesangial hypercellularity, 2-mesangial expansion and 3-focal segmental
glomerulosclerosis that were determined in a semi-quantitative basis (score 0–3 for the former two parameters, score 0–0.3 for glomerulosclerosis).
Relevant results observed after 7 days are presented in this figure (A). Specific patterns are shown in (B); stains are hematoxylin eosin for all with the
exception of Masson Blue stain for LPS alone.
doi:10.1371/journal.pone.0111285.g002
IL-2, Tregs and LPS Nephropathy
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Figure 3. Treg level regulation by IL-2 and IL-2/anti-IL-2. Peripheral (A) and spleen/lymph nodes (B) Tregs levels were evaluated at several
intervals after IL-2 and IL-2/anti-IL-2 treatment and after LPS in both WT and P2672/2mice. In the case of IL-2, determination of circulating and tissue
Tregs was done after 7 and 14 days from IL-2 that is the time potentially required to achieve a regulatory effect of the cytokine [21].; Tregs were also
determined 3 days after LPS that means 17 days from IL-2 treatment. The time required for a regulatory effect of IL-2/anti-IL-2 is instead 5 days. Treg
levels were accordingly determined at this time (i.e. 5 days after IL-2/anti-IL-2) and after 3 days from LPS corresponding to 8 days of treatment. * = p#
0.05, ** = p#0.005, *** = p#0.0005.
doi:10.1371/journal.pone.0111285.g003
IL-2, Tregs and LPS Nephropathy
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As expected, Tregs were increased both in peripheral blood and
secondary lymphoid organs (spleen and lymph nodes) after
infusion of the IL-2/anti-IL-2 complex while a minimal increase
was observed in mice receiving IL-2 alone [21]. The effects of both
compounds (i.e. IL-2 and IL-2/anti-IL-2) on proteinuria were,
instead, similar with IL-2 playing the most substantial protective
effect. In contrast, lack of P267 activity did not influence
proteinuria implying that ATP is not directly involved in the
podocyte damage. This requires further study since it is in
apparent contrast with what already reported on a blunted
podocyte damage by LPS is when P267 is deleted. [39].
We observed a clear dichotomy between Tregs (highest
numbers in mice treated with IL-2/anti-IL-2) and proteinuria
(minimal in mice treated with IL-2). Altogether these results
suggest that the protective effect of IL-2 is not linked to
enhancement of Tregs functional activity. On the other hand,
looking at renal histology it is clear that all parameters evaluated
(i.e. mesangial hypercellularity and matrix expansion) were not
modified by IL-2 and the same amount of glomerulosclerosis after
7 days from LPS was notable in all mice in spite of different
treatments. Once again, there is a dichotomy between proteinuria
and major renal modifications that implies IL-2 effect on
proteinuria is ancillary to the mechanism of glomerulosclerosis
Figure 4. TLR-4 urine levels. Urine deriving from the same mice of the above experiments were utilized for determining levels of TLR-4, a molecule
that interacts with LPS [10]. After LPS infusion, urine TLR-4 increased dramatically and then decreased in the following 72 hours. In mice treated with
the combination of IL2 and LPS, urine TLR-4 levels were reduced by 1200% compared to LPS alone and then normalized in the 72 hours after. IL-2/
anti-IL-2 produced intermediate effects.
doi:10.1371/journal.pone.0111285.g004
IL-2, Tregs and LPS Nephropathy
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and of limited importance. One possibility is that IL-2 modifies
other factors directly linked to proteinuria without affecting the
overall process of sclerosis, glomerular hemodynamics represent-
ing a potential candidate [40]. Modification of other immuno-
competent cells and/or molecules should be considered. NK and
CD4+/CD8+ cells are, in fact, induced by IL-2 and potentially
modify B7-1 expression in podocytes by secreting soluble
mediators (IL-10, TGF b and CTLA-4). Actually, we observed a
marked decrease of TLR-4 urine excretion in mice treated with
the combination of LPS and IL-2 that was instead, as known, very
high in mice treated with LPS alone. In APC, LPS is a strong
inducer of B7-1 through TLR-4 signaling [28] therefore, reduced
TLR-4 would explain reduced B7-1 activation and LPS toxicity.
While, this could explain the acute effect on proteinuria of IL-2
several and crucial aspects related to glomerulosclerosis remain
unexplained. Historical data in human beings and in experimental
nephrosis [41,42] suggest that renal evolution to glomerulosclerosis
and interstitial fibrosis (that are the two hallmarks of progressive
renal lesions) is independent to any acute damage and is unique for
several renal pathologies (from toxic, to immununologic, meta-
bolic, etc.) mostly linked to hemodynamic conditions. It is possible
that similar mechanisms are involved in accelerating progression
to sclerosis in mice with LPS nephropathy.
Therefore, the results of our study do not support the general
concept of Tregs mediated protection in animal models of
immune-mediated renal diseases. Induction of Tregs attenuated
proteinuria in Buffalo/Mna rats, a model of spontaneous
nephrotic syndrome associated with focal segmental glomerulo-
sclerosis [18] and also led to regression of these lesions in post-
transplant recurrence of the disease. In a similar way, transfer of
Foxp3-transduced T cells reduced proteinuria and renal glomer-
ulosclerosis in rats treated with Adriamycin, a murine model of
chronic proteinuria leading to renal failure [19]. Finally,
administration of the same IL-2/anti-IL-2 antibodies used in our
study was renoprotective in mice treated with Adriamycin showing
less histological injury, better renal function and less inflammation
[43].
In spite of the inconsistencies mentioned above, the findings on
IL-2 protection in LPS nephropathy come in the mid of a road
where low-dose IL-2 is considered for human use [44]. The most
remarkable application is in patients with HCV related vasculitis
in which case resolution of infection correlates with recovery of
Tregs levels [20]. Circulating levels of IL-2 and Tregs in nephrotic
syndrome have been also investigated in the past in view of the
general concept that nephrotic syndrome is a T cell disorder
[45,46]. Studies on Tregs and more in general on cytokines in
humans are scanty. Araya and col [47] described an impaired
Tregs function in patients with steroid resistant nephritic
syndrome but the analysis of IL-2 levels were inconsistent for a
role of this cytokine.
In conclusion, the results of this study confirm the positive
regulation of Tregs by IL-2/anti-IL-2 complex while IL-2 alone
had no effect. They also show that proteinuria in LPS
nephropathy is not sensitive to modulation by Tregs while it can
be reduced by infusion of IL-2. Renal lesions of glomerulosclerosis
were not modified by IL-2 and IL-2/anti-IL-2 implying that other
factors influence renal homeostasis following LPS. Finally, mice
lacking P267 had the same proteinuria and renal lesions of wild-
type mice treated with LPS suggesting that both extracellular ATP
via P267 stimulation and Tregs stability by P267 blockade are
not crucially involved in proteinuria/renal lesions in this model.
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